ERJ Open Research最新文献

{"title":"Systemic pro-inflammatory response following bronchoscopic lung volume reduction using endobronchial valves.","authors":"Jorine E Hartman, Marieke C van der Molen, Marnix R Jonker, Rein Posthuma, Lowie E G W Vanfleteren, Dirk-Jan Slebos, Simon D Pouwels","doi":"10.1183/23120541.00665-2024","DOIUrl":"10.1183/23120541.00665-2024","url":null,"abstract":"<p><strong>Rationale: </strong>Bronchoscopic lung volume reduction treatment using endobronchial valves (EBV) is an effective treatment for severe COPD patients by improving lung function and quality of life. However, little is known about its effects on systemic inflammation. Therefore, the aim of our study was to investigate whether EBV treatment impacts the inflammatory cytokine profile.</p><p><strong>Methods: </strong>This study was a predefined sub-study of the SoLVE trial (NCT03474471) that investigated the combination of EBV treatment with pulmonary rehabilitation (PR). The sub-study included the collection of blood samples with assessment of 10 inflammatory markers prior to EBV treatment and 6 months after EBV or EBV+PR treatment.</p><p><strong>Results: </strong>In 66 patients, 6 months after treatment a pro-inflammatory cytokine profile was observed, with an increase in all pro-inflammatory markers and a decrease in the anti-inflammatory cytokine interleukin-10. The changes in plasma cytokine profile were not associated with changes in clinical outcomes such as lung function or exercise capacity.</p><p><strong>Discussion: </strong>In conclusion, our study demonstrated an elevation in systemic pro-inflammatory cytokine levels following successful EBV treatment, which was not associated with adverse clinical outcomes. It would be interesting to further explore whether this increase is attributed to a foreign body response or if other factors contribute to this phenomenon.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11895102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ERS Congress 2024: highlights from the Allied Respiratory Professionals Assembly.","authors":"Astrid Blondeel, Madeleine Driskel, Anke Lenferink, Lian Trapman, Jellien Makonga-Braaksma, Daniel Langer, Heleen Demeyer","doi":"10.1183/23120541.01145-2024","DOIUrl":"10.1183/23120541.01145-2024","url":null,"abstract":"<p><p><b>This article summarises highlights from #ERSCongress including 1) the rapidly advancing use of digital health and AI, 2) keys to effective self-management, and 3) an update on the ongoing debate on race and ethnicity in pulmonary function testing</b> https://bit.ly/3ZPrlZw.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11895098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natural killer cells in the lung: novel insight and future challenge in the airway diseases.","authors":"Tommaso Pianigiani, Irene Paggi, Grace E Cooper, Karl J Staples, Melissa McDonnell, Laura Bergantini","doi":"10.1183/23120541.00683-2024","DOIUrl":"10.1183/23120541.00683-2024","url":null,"abstract":"<p><p>Natural killer (NK) cells are innate lymphoid cells which are present in the lung as circulating and resident cells. They are key players both in airway surveillance and in crosstalk with (COPD) pathogenesis, and they seem to contribute to the development of bronchiectasis. In asthma, NK cell dysfunction was observed mainly in severe forms, and it can lead to a biased type-2 immune response and failure in the resolution of eosinophilic inflammation that characterise both allergic and eosinophilic phenotypes. Moreover, aberrant NK cell functions may interfere with antimicrobial immune response contributing to the frequency and severity of virus-induced exacerbations. In COPD, lung NK cells exhibit increased cytotoxicity against lung epithelium contributing to lung tissue destruction and emphysema. This cell destruction may be exacerbated by viral infections and cigarette smoke exposure through NKG2D-dependent detection of cellular stress. Lastly, in bronchiectasis, the airway NK cells might both promote neutrophil survival following stimulation by proinflammatory cytokines and promote neutrophil apoptosis. Systemic steroid treatment seemingly compromises NK activity, while biologic treatment with benralizumab could enhance NK cell proliferation, maturation and activation. This narrative review gives an overview of NK cells in airway diseases focusing on pathophysiological and clinical implications. Together, our findings emphasise the pleiotropic role of NK cells in airway diseases underscoring their possible implications as to therapeutical approaches.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11895099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The lung proteome in HIV-associated obstructive lung disease.","authors":"Sarah Samorodnitsky, Danielle Weise, Eric F Lock, Ken M Kunisaki, Alison Morris, Janice M Leung, Monica Kruk, Laurie Parker, Pratik Jagtap, Timothy J Griffin, Chris H Wendt","doi":"10.1183/23120541.00204-2024","DOIUrl":"10.1183/23120541.00204-2024","url":null,"abstract":"<p><strong>Rationale: </strong>Obstructive lung disease is increasingly common among persons living with HIV (PLWH). There are currently no validated biomarkers that identify individuals at risk of developing obstructive lung disease (OLD), and specific mechanisms contributing to HIV-associated OLD remain elusive, independent of smoking. We sought to identify biomarkers and biological pathways associated with OLD using a broad proteomic approach.</p><p><strong>Methods: </strong>We performed tandem mass tagging and mass spectrometry (MS) analysis on bronchoalveolar lavage fluid samples from persons living with HIV with OLD (n=26) and without OLD (n=26). We combined untargeted MS with a targeted SomaScan aptamer-based approach. We used Pearson correlation tests to identify associations between each protein and lung function (forced expiratory volume in 1 s (FEV₁) % pred). We adjusted for multiple comparisons using a false discovery rate adjustment. Significant proteins were entered into a pathway over-representation analysis. Protein-driven endotypes were constructed using K-means clustering.</p><p><strong>Measurements and main results: </strong>We identified over 3800 proteins by MS and identified 254 proteins that correlated with FEV₁ % pred when we combined the MS and SomaScan proteomes when adjusting for smoking status. Pathway analysis revealed cell adhesion molecules as significant.</p><p><strong>Conclusions: </strong>Protein expression differs in the lung of PLWH and decreased lung function (FEV₁ % pred). Pathway analysis reveals cell adhesion molecules having potentially important roles in this process.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11874292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does adding digital inhalers to asthma triple therapy result in quadruple therapy?","authors":"Job F M van Boven, Amber A Eikholt","doi":"10.1183/23120541.01026-2024","DOIUrl":"10.1183/23120541.01026-2024","url":null,"abstract":"<p><p><b>Digital inhalers: adequate subgroup targeting and cost-effective implementation in asthma care remain key challenges</b> https://bit.ly/3UTWtWv.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11874138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating digital adherence support in asthma: the ADITION non-interventional study.","authors":"Holger Woehrle, Jens Driemert, Lukas Jerrentrup, Conrad Schiefer, Gregor Bushart, Inessa Schwab Sauerbeck","doi":"10.1183/23120541.00734-2024","DOIUrl":"10.1183/23120541.00734-2024","url":null,"abstract":"<p><strong>Background: </strong>Poor adherence to asthma maintenance therapy is associated with worse outcomes. A solution could be digital adherence support. This study evaluated asthma control and adherence in patients using mometasone furoate/indacaterol/glycopyrronium (MF/IND/GLY) with a digital support system or using any inhaled corticosteroid/long-acting β₂-agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) combination without support.</p><p><strong>Methods: </strong>This prospective, non-interventional, multicentre, open-label study enrolled adults with asthma in Germany. Prior to inclusion, treatment was initiated with MF/IND/GLY with digital support or with any ICS/LABA/LAMA without digital support. The primary end-point was change in Asthma Control Test (ACT) at 6 months.</p><p><strong>Results: </strong>Of 222 and 203 patients in the MF/IND/GLY plus digital support and ICS/LABA/LAMA groups, 76.1% and 74.9% completed follow-up, respectively. Baseline mean ACT total scores were 17.0 and 14.7, with mean changes from baseline at 6 months of 3.0 and 4.1, respectively; following propensity matching (n=92 per group), mean changes were similar in the two groups, with overlapping 95% confidence intervals (2.9 (95% CI 1.9-3.9) and 4.0 (95% CI 3.0-5.1), respectively). At enrolment, patients were overall moderately adherent to maintenance therapy, with limited changes over the study. The overall incidence of adverse events was similar in the two groups (29.5% and 27.3% of patients, respectively).</p><p><strong>Conclusions: </strong>Patients using MF/IND/GLY with digital support had similar improvements in asthma control to those receiving ICS/LABA/LAMA alone, with minimal changes in adherence. These results illustrate the challenges in evaluating asthma control and adherence in non-interventional studies. Further studies are required to evaluate the value of digital support systems and how they can be used to optimise inhaler adherence.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11874225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of CFTR modulators in patients with interstitial lung disease caused by ABCA3 transporter deficiency.","authors":"Mathilde Le Brun, Nadia Nathan, Camille Louvrier, Marie Legendre, Severine Feuillet, Justine Frija-Masson, Mwetty Onanga, Lise Morer, Marie-Pierre Debray, Isabelle Fajac, Pierre-Régis Burgel, Sylvain Marchand-Adam, Bruno Crestani, Raphaël Borie","doi":"10.1183/23120541.00701-2024","DOIUrl":"10.1183/23120541.00701-2024","url":null,"abstract":"<p><p><b>CFTR modulators may be valuable therapy for patients with ABCA3 pathogenic variants</b> https://bit.ly/3TMWKK9.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11874218/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung recruitment manoeuvre strategies in paediatric intensive care units across Europe.","authors":"Elisa Poletto, Marco Daverio, Robert George Theodoor Blokpoel, Gloria Brigiari, Dario Gregori, Marti Pons-Odena, Alvise Tosoni","doi":"10.1183/23120541.00781-2024","DOIUrl":"10.1183/23120541.00781-2024","url":null,"abstract":"<p><strong>Introduction: </strong>In severe paediatric acute respiratory distress syndrome (PARDS) lung recruitment manoeuvres (LRMs) may be applied to improve oxygenation, but their application is still controversial. The aim of this survey is to report what the current practice is across European paediatric intensive care units (PICUs).</p><p><strong>Methods: </strong>An online survey was distributed to PICUs in 19 European countries targeting paediatric intensivists, nurses and respiratory therapists. One reply per unit was allowed.</p><p><strong>Results: </strong>151 PICUs out of 276 (54.8%) responded. Of those, 75.9% have more than 300 admissions per year and 45.1% are extracorporeal membrane oxygenation (ECMO) centres. LRMs are employed in 78.9% of surveyed PICUs. Twenty-three out of 105 (21.9%) PICUs have a standardised protocol. LRMs are mainly performed by physicians (99%), supported by nurses (38.4%) and/or respiratory therapists (11.5%). The main reported contraindications are air leak (86.7%), haemodynamic instability (75.2%) and intracranial hypertension (63.8%). Staircase recruitment manoeuvres (SRMs) are the most commonly (69.5%) practiced LRMs, while sustained inflation is used in 44.8% of PICUs, alone or in addition to SRMs. The success of LRMs is measured through oxygenation improvement (oxygenation index or arterial oxygen tension/inspiratory oxygen fraction). Profound hypotension is the most reported complication (49.5%), while 35.2% did not report any complication. Lack of familiarity is the main obstacle to the application of LRMs (67.9%).</p><p><strong>Conclusions: </strong>To our best knowledge this is the first survey providing an overview of current LRMs application among European PICUs. Practise is diverse among countries and PICUs. Further research is necessary to build stronger evidence to support a more standard application of LRMs.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11873995/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The interstitial lung disease patient pathway: from referral to diagnosis.","authors":"Graham Lough, Rayid Abdulqawi, Gina Amanda, Katerina Antoniou, Arata Azuma, Milind Baldi, Ahmed Bayoumy, Jürgen Behr, Elisabeth Bendstrup, Demosthenes Bouros, Kevin Brown, Nazia Chaudhuri, Tamera J Corte, Vincent Cottin, Bruno Crestani, Kevin R Flaherty, Ian Glaspole, Leticia Kawano-Dourado, Michael P Keane, Martin Kolb, Fernando J Martinez, Maria Molina-Molina, Iñigo Ojanguren, Laurence Pearmain, Ganesh Raghu, Paola Rottoli, Stefan C Stanel, Gabriela Tabaj, Carlo Vancheri, Brenda Varela, Bonnie Wang, Athol Wells, Pilar Rivera-Ortega","doi":"10.1183/23120541.00899-2024","DOIUrl":"10.1183/23120541.00899-2024","url":null,"abstract":"<p><strong>Background: </strong>Suspected interstitial lung disease (ILD) patients may be referred to an ILD-specialist centre or a non-ILD-specialist centre for diagnosis and treatment. Early referral and management of patients at ILD-specialist centres has been shown to improve survival and reduce hospitalisations. The COVID-19 pandemic has affected the ILD patient diagnostic pathway and prompted centres to adapt. This study investigates and contrasts ILD patient pathways in ILD-specialist and non-ILD-specialist centres, focusing on referrals, caseloads, diagnostic tools, multi-disciplinary team (MDT) meeting practices and resource accessibility.</p><p><strong>Methods: </strong>Conducted as a cross-sectional study, a global self-selecting survey ran from September 2022 to January 2023. Participants included ILD specialists and healthcare professionals (HCPs) from ILD-specialist centres and non-ILD-specialist centres.</p><p><strong>Results: </strong>Of 363 unique respondents from 64 countries, 259 were from ILD-specialist centres and 104 from non-ILD-specialist centres. ILD centres had better resource availability, exhibiting higher utilisation of diagnostic tests (median: 12 tests) than non-ILD centres (nine tests) and better access to specialist professions attending MDT meetings (median: six professions at meeting) in specialist centres than non-ILD centres (three professions at meeting). Transitioning to virtual MDT meetings allowed HCPs from other locations to join meetings in nearly 90% of all centres, increasing regular participation in 60% of specialist centres and 72% of non-ILD centres. For treatment of patients, specialist centres had better access to antifibrotic drugs (91%) compared to non-ILD centres (60%).</p><p><strong>Conclusions: </strong>Diagnostic pathways for ILD patients diverged between specialist centres and non-ILD centres. Disparities in resource and specialist availability existed between centres.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11874298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in ventilatory muscle recruitment and work of breathing in COPD and interstitial lung disease.","authors":"Ben Fabry","doi":"10.1183/23120541.00881-2024","DOIUrl":"10.1183/23120541.00881-2024","url":null,"abstract":"<p><p><b>Providing more detailed explanations would help readers better understand and correctly interpret the reported data</b> https://bit.ly/3N72niA.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11873994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}